HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

WRC 213

has antineoplastic activity; structure in first source

Also Known As:

WRC-213; WRC213

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Chan, Ya-Ling: 1 article (02/2008)
2.	Guh, Jih-Hwa: 1 article (02/2008)
3.	Hsiao, Che-Jen: 1 article (02/2008)
4.	Hsin, Ling-Wei: 1 article (02/2008)
5.	Lee, Chien-Hua: 1 article (02/2008)
6.	Li, Tsia-Kun: 1 article (02/2008)
7.	Liao, Cho-Hwa: 1 article (02/2008)
8.	Lyu, Ping-Chiang: 1 article (02/2008)

Related Diseases

1.	Cardiotoxicity 02/15/2008 - "In conclusion, it is suggested that WRC-213 is a potential topoisomerase II inhibitor with reduced cardiotoxicity and drug resistance. " 02/15/2008 - "WRC-213, an l-methionine-conjugated mitoxantrone derivative, displays anticancer activity with reduced cardiotoxicity and drug resistance: identification of topoisomerase II inhibition and apoptotic machinery in prostate cancers." 02/15/2008 - "Moreover, the assessment of cytotoxicity in H9c2 cardiomyocytes and drug resistance in NCI/ADR-RES cells demonstrated that WRC-213 showed much lower cardiotoxicity and P-glycoprotein-related resistance than those of mitoxantrone, etoposide and doxorubicin. "
2.	Colorectal Neoplasms (Colorectal Cancer) 02/15/2008 - "In an extension evaluation, WRC-213 displayed a potent anti-proliferative activity in various cancer cell lines, including non-small cell lung cancer A549, androgen-independent prostate cancer DU145, colorectal cancer HT-29, breast cancer MCF-7 and hepatocellular carcinoma Hep3B and HepG2. "
3.	Prostatic Neoplasms (Prostate Cancer) 02/15/2008 - "The screening tests showed that WRC-213, an l-methionine conjugation, was the most effective derivative to inhibit proliferative effect of human androgen-independent prostate cancer PC-3 cells (IC50=50 nM). " 02/15/2008 - "WRC-213, an l-methionine-conjugated mitoxantrone derivative, displays anticancer activity with reduced cardiotoxicity and drug resistance: identification of topoisomerase II inhibition and apoptotic machinery in prostate cancers." 02/15/2008 - "In an extension evaluation, WRC-213 displayed a potent anti-proliferative activity in various cancer cell lines, including non-small cell lung cancer A549, androgen-independent prostate cancer DU145, colorectal cancer HT-29, breast cancer MCF-7 and hepatocellular carcinoma Hep3B and HepG2. "
4.	Neoplasms (Cancer) 02/15/2008 - "In an extension evaluation, WRC-213 displayed a potent anti-proliferative activity in various cancer cell lines, including non-small cell lung cancer A549, androgen-independent prostate cancer DU145, colorectal cancer HT-29, breast cancer MCF-7 and hepatocellular carcinoma Hep3B and HepG2. "
5.	Hepatocellular Carcinoma (Hepatoma) 02/15/2008 - "In an extension evaluation, WRC-213 displayed a potent anti-proliferative activity in various cancer cell lines, including non-small cell lung cancer A549, androgen-independent prostate cancer DU145, colorectal cancer HT-29, breast cancer MCF-7 and hepatocellular carcinoma Hep3B and HepG2. "

Related Drugs and Biologics

1.	Topoisomerase II Inhibitors
2.	Member 1 Subfamily B ATP Binding Cassette Transporter
3.	Mitoxantrone (Novantrone)
4.	Methionine (L-Methionine)
5.	Etoposide (VP 16)
6.	Doxorubicin (Adriamycin)
7.	Type II DNA Topoisomerases (Topoisomerase II)
8.	Androgens